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Abstract
Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. In fact, low-density
lipoprotein (LDL)-lowering drugs have anti-inflammatory effects. The Canakinumab Antiinflammatory Thrombosis
Outcome Study (CANTOS) has shown that interleukin (IL)-1b blockade reduces the incidence of cardiovascular
events in patients with previous myocardial infarction and C-reactive protein levels >2 mg/L. These data confirm the
connection between lipids and inflammation, as lipids activate the Nod-like receptor protein 3 inflammasome that leads
to IL-1b activation. LDL-lowering drugs are the foundation of cardiovascular prevention. Now, the CANTOS trial
demonstrates that combining them with IL-1b blockade further decreases the incidence of cardiovascular events.
However, both therapies are not at the same level, given the large evidence showing that LDL-lowering drugs reduce
cardiovascular risk as opposed to only one randomized trial of IL-1b blockade. In addition, IL-1b blockade has only been
studied in patients with C-reactive protein >2 mg/L, while the benefit of LDL-lowering is not restricted to these patients.
Also, lipid-lowering drugs are not harmful even at very low ranges of LDL, while anti-inflammatory therapies may confer
a higher risk of developing fatal infections and sepsis. In the future, more clinical trials are needed to explore whether
targeting other inflammatory molecules, both related and unrelated to the IL-1b pathway, reduces the cardiovascular
risk. In this regard, the ongoing trials with methotrexate and colchicine may clarify whether the cardiovascular benefit of
IL-1b blockade extends to other anti-inflammatory mechanisms. A positive result would represent a major change in the
future treatment of atherosclerosis.
1Fundacio´n Jime´nez Dı´az, Auto´noma University and CiberCV, Madrid,
Spain
2Karolinska University Hospital, Stockholm, Sweden
3Karolinska Institutet, Stockholm, Sweden
4Cardiovascular Sciences Institute (ICCC) and CiberCV, Hospital de la
Santa Creu i Sant Pau, Barcelona, Spain
5University of Geneva, Switzerland
6L’Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes,
France
7Academic Medical Centre, Amsterdam, The Netherlands
8Fundacio´n Jime´nez Dı´az, Auto´noma University and CIBERDEM, Madrid,
Spain
9University of Sheffield, UK
10University of Amsterdam, The Netherlands
11Institute for Cardiovascular Prevention, LMU Munich and German
Centre for Cardiovascular Research (DZHK), partner site Munich Heart
Alliance, Germany
12University Heart Centre, University Hospital Zurich and Centre for
Molecular Cardiology, University of Zurich, Switzerland
13Kennedy Institute, NDORMS, University of Oxford, UK
14INSERM UMR-1048, Institute of Metabolic and Cardiovascular
Diseases, Toulouse, France
15Cardiovascular Research Institute Maastricht, Maastricht University,
The Netherlands
16University Medical Centre Utrecht, Netherlands
Corresponding author:
Jose´ Tun˜o´n, Department of Cardiology, Fundacio´n Jime´nez Dı´az, Avenida
Reyes Cato´licos 2, 28040 Madrid, Spain.
Email: jtunon@fjd.es
European Journal of Preventive
Cardiology
2018, Vol. 25(9) 948–955
! The European Society of
Cardiology 2018
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2047487318773384
journals.sagepub.com/home/ejpc
Keywords
Lipids, inflammation, immune response, atherosclerosis, interleukin-1b, canakinumab
Received 1 December 2017; accepted 31 March 2018
Introduction
Lipids play a pivotal role in atherosclerosis.
Inflammation has also been acknowledged as a key bio-
logical process in this disorder.1 Importantly, dyslipi-
daemia and inflammation are closely intertwined in
their contribution to atherosclerosis and cardiovascular
risk.2 Hence, low-density lipoprotein (LDL)-lowering
drugs that effectively decrease cardiovascular events
have also anti-inflammatory effects.3 However, some
of the anti-inflammatory effects reported for statins,
and also for aspirin and renin–angiotensin modula-
tors,3–5 may result from LDL-lowering, antithrombotic
or anti-proliferative effects, and from an improved
endothelial function.
Observational studies have suggested beneficial
effects of anti-inflammatory drugs in terms of cardiovas-
cular risk reduction.6 However, until recently, evidence
on the efficacy of anti-inflammatory strategies to reduce
cardiovascular events in humans was lacking. Thus,
there was a need for a definitive study to specifically
address the potential influence of inflammatory suppres-
sion on the incidence of cardiovascular events.
The recent Canakinumab Antiinflammatory
Thrombosis Outcomes Study (CANTOS) has shown,
in patients on statin therapy but with elevated
C-reactive protein (CRP) levels, a significant reduction
of cardiovascular events by the inhibition of interleu-
kin-1b (IL-1b) without further influencing lipid levels.7
These results introduce a new paradigm for the treat-
ment of human atherosclerosis and cardiovascular dis-
ease. In this Consensus Paper, we highlight the role of
inflammation and dyslipidaemia in atherosclerosis and
aim to outline the new issues and challenges that are
brought up by the interplay between these two risk fac-
tors in cardiovascular prevention.
Lipid-induced inflammatory responses
(Figure 1)
A key trigger of atherosclerosis is subintimal retention
of LDL at regions of complex flow or low shear stress.8
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Figure 1. Lipid dysregulation triggers inflammatory and immune responses.
AP-1: activator protein-1; CCR2: chemokine receptor type-2; COX2: cyclooxygenase-2; DC: dendritic cells; FH: familial hypercho-
lesterolaemia; IKK: IkB kinase; IL-1b: interleukin-1b; IL-6: interleukin 6; IL1R: interleukin-1 receptor; INFg: interferon-g; JAK-STAT:
Janus kinase and signal transducer activator of transcription proteins; JNK: Jun kinase; LDL: low-density lipoprotein; mLDL: modified
LDL; Mø: macrophages; MCP-1: monocyte chemoattractant protein-1; NF-kB: nuclear factor-kB; NLR: Nod-like receptors; oxLDL:
oxidized LDL; PMN: polymorphonuclear; PRR: pattern recognition receptors; ROS: reactive oxygen species; Scav-R: scavenger
receptors; SRA and SRB: scavenger receptor class A and B; TGFb: transforming growth factor-b; Th: T helper cell; TLR: toll-like
receptor; TNFa: tumour necrosis factor-a; TNF-R: tumour necrosis factor-receptor; Treg: T regulatory cell; VCAM: vascular cell
adhesion molecule.
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Modified LDLs are strong inducers of inflammation
and have a marked impact on atherosclerosis. They
alter vascular physiology by activating pattern recogni-
tion receptors, such as toll-like receptors (TLRs), which
trigger proinflammatory signals and reactive oxygen
species and promote matrix degradation.9–12 These
TLRs will prime the Nod-like receptor protein 3
(NLRP3) inflammasome for activation by cholesterol
crystals leading to IL-1b activation13 (Figure 2). This
leads to the increased release of cytokines and activates
the endothelium by enhancing the expression of adhe-
sion molecules and chemokines, costimulatory mol-
ecules, such as CD40, and pro-inflammatory
transcription factors such as nuclear factor-kB
(NF-kB),14–16 promoting the recruitment of inflamma-
tory cells into the vascular wall. Among them, macro-
phages are of key relevance since they can scavenge
oxidized LDL17 evolving into pro-atherogenic foam
cells.1,6,18 Also, in atherosclerosis there is an enhanced
haematopoietic activity in the bone marrow and LDL
stimulates the capacity of haematopoietic stem and pro-
genitor cells to differentiate into inflammatory cells.19
Adaptive immune responses play a key role in
atherogenesis. Activated T lymphocytes are present in
both peripheral blood and coronary atherosclerotic pla-
ques in patients with acute coronary syndromes,1,20 and
especially T helper h1-derived cytokines such as tumour
necrosis factor a (TNFa), and interferon-gamma are
associated with atherosclerosis. The notion of immuno-
modulatory effects of LDL-lowering agents emerged
from both experimental and clinical studies,21,22 thus,
the causal relation between lipids and immunity with
regard to atherogenesis has been heavily investigated in
the recent two decades.
Anti-inflammatory effects of
LDL-lowering therapies
There is overwhelming evidence indicating that statins
have anti-inflammatory and immunomodulatory
effects. They decrease the activity of the transcription
factor NF-kB,3 with subsequent diminution in the
expression of adhesion molecules, cytokines23 and
metalloproteinases (MMPs), interfering also with the
arachidonic/cyclooxygenase pathway.24 Also, they
reduce plasma levels of inflammatory markers such as
CRP.25 Although most evidence has been obtained with
statins, other LDL-lowering approaches have shown
some anti-inflammatory effects. For instance, ezetimibe
and fibrates also inhibit the NF-kB pathway and
decrease CRP levels.26–29 Similarly, low fat diet reduces
CRP levels30 and Mediterranean diet, which decreases
the LDL/high-density lipoprotein cholesterol ratio,31
reduces CD40 expression on monocytes and plasma
levels of cell adhesion molecules and cytokines.32
Recently, another class of LDL-lowering drugs, pro-
protein convertase subtilisin/kexin type 9 (PCSK9)
human monoclonal antibodies (mab), has been demon-
strated to reduce the incidence of cardiovascular
events.33,34 PCSK9 mab do not decrease plasma levels
of CRP and other inflammatory markers.35–37
However, they reduce levels of lipoprotein(a)38 – a mol-
ecule that promotes inflammation, oxidative stress and
coagulation – and decrease monocyte activation and
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Figure 2. Interleukin-1b as a connection in the mechanism of action of LDL-lowering therapy and canakinumab. Modified LDL
promotes the synthesis of pro-IL-1b, while cholesterol crystals, among other stimuli, assemble the components of the inflammasome
activating caspase-1, leading to IL-1b synthesis. Then, IL-1b synthesis may be inhibited by LDL-lowering therapies, while canakinumab
binds to IL-1b, inhibiting its effects.
ASC: adaptor protein; IL-1b: interleukin-1b; LDL: low-density lipoprotein; mLDL: modified LDL; NF-kB: nuclear factor-kB; NLRP3:
Nod-like receptor protein 3; TLR: toll-like receptor.
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transmigration in patients with familial hypercholester-
olaemia.35 Moreover, PCSK9 inhibition in atheroscler-
otic mice diminished macrophage and necrotic core
content.39 These findings suggest that plasma bio-
markers may not always represent an exact indicator
of the degree of inflammation at the arterial wall. In
addition, up-regulation of hepatic LDL receptors
(LDLRs) by PCSK9 inhibition results in increased lipo-
polysaccharide clearance, and decreased inflammatory
response during sepsis in mice.40,41 In this regard,
patients with PCSK9 loss-of-function variants exhibit
improved clinical outcomes during septic shock.42
Likewise, PCSK9 expression can be experimentally
induced by pro-inflammatory molecules, such as
lipopolysaccharide and TNFa among others.43,44 Also,
PCSK9 modulates LDLR expression in macrophages,45
promoting the expression of pro-inflammatory markers
and inhibiting anti-inflammatory molecules.45 In
humans, plasma PCSK9 concentrations are positively
associated with white blood cell count and fibrinogen
in patients with coronary artery disease.46 Then, these
evidences show that LDL-lowering therapies other than
statins can decrease inflammation.
Anti-inflammatory therapy and
cardiovascular risk
Inflammatory cytokines such as IL-1b47 and TNF-a48
have been detected in human coronary atherosclerosis.
Observational studies have revealed an association of
different anti-inflammatory treatments, when used for
their indications, with reduced cardiovascular risk, pro-
viding support for the concept of inflammation reduc-
tion in cardiovascular prevention.6 This is the case for
anti-TNF therapy in rheumatoid arthritis49,50 and anti-
leukotrienes in asthmatics51 that apparently decreased
the incidence of cardiovascular events but were never
tested in randomized clinical trials. On the other hand,
other anti-inflammatory drugs failed to decrease the
cardiovascular risk, as was observed for steroids in
patients with unstable angina.52 However, large studies
and clinical trials until now have shown that, with the
exception of aspirin, non-steroidal anti-inflammatory
drugs in general are associated with an increased car-
diovascular risk,53–56 indicating that their use should be
limited to patients without other alternatives.54
The recent CANTOS trial sheds new light on the
relationship of inflammation with atherosclerosis.7 In
this randomized, double-blind trial, 10,061 patients
with a previous myocardial infarction, the majority
using moderate to high intensity statin therapy, and
CRP> 2mg/L received canakinumab, a monoclonal
antibody that blocks IL-1b, or placebo. After a
median follow-up of 3.7 years there was a 15%
decrease in the incidence of the primary end point
composed of non-fatal myocardial infarction and
non-fatal stroke. While there was an increase in the
incidence of fatal infections, neutropenia or thrombo-
cytopenia in patients on canakinumab, there were also
non-cardiovascular benefits, comprising a reduction in
the incidence of lung cancer, cancer mortality, arthritis
and gout, although no difference in total mortality was
observed between groups.7,57
Impact of the CANTOS trial on our
understanding of interplay between lipids
and inflammation
In addition to demonstrating that targeting inflamma-
tion can be effective in the treatment of atherosclerosis,
the results from the CANTOS trial provide a first proof
of principle about the link between lipids and inflam-
mation. As mentioned above, cholesterol crystals acti-
vate the NLRP3 inflammasome, leading to IL-1b
activation13 (Figure 2) and non-canonical pathways of
activation also exist.58 Since IL-1 can activate itself,59
blocking this pathway with canakinumab could
attenuate this effect of lipids.
Interestingly, it has been shown that inflammation
can induce dyslipidaemia through different mechan-
isms.60,61 However, the effects of anti-inflammatory
and immunosuppressive therapies on lipids are vari-
able, with both favourable and adverse lipid profiles
having been reported,62–64 probably depending of the
population studied and the drug used.63 In this trial,
canakinumab did not decrease lipid levels, while it
slightly increased triglyceride levels.57 Thus, the
CANTOS data exclude the possibility that canakinu-
mab reduces cardiovascular risk through lipid-depen-
dent mechanisms linked to IL-1b.
Patients in the CANTOS trial had mean LDL levels
of approximately 80mg/dL and CRP> 2mg/L. Efforts
to further reduce residual cardiovascular risk now have
multiple options. The prespecified analysis of the
Further Cardiovascular Outcomes Research With
PCSK9 Inhibition in Subjects With Elevated Risk
study showed that the cardiovascular-benefit of LDL
lowering with PCSK9 mab is extended to very low LDL
values, finding a 31% reduction in the incidence of the
primary end point in patients achieving levels of 10mg/
dL as compared with those with 100mg/dL or higher.65
Similarly, CANTOS demonstrates that in patients
showing a reduction of CRP levels below 2mg/L fol-
lowing canakinumab administration, a 31% risk reduc-
tion in both total and cardiovascular mortality is
observed as compared with no benefit in those with
CRP levels of 2mg/L or above.66 However, the large
body of evidence linking LDL lowering to a reduction
in cardiovascular risk clearly favours the use of PCSK9
mab.33,67 In the future, it would be interesting to
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explore the cardiovascular effect of other anti-
inflammatory therapies, including those directed at reg-
ulating IL-1, for example, anakinra68 or other upstream
IL-1 related molecules.69 In this regard, the Colchicine
Cardiovascular Outcomes Trial (COLCOT) (https://
clinicaltrials.gov/ct2/show/NCT02551094) and the
Cardiovascular Inflammation Reduction Trial
(CIRT)70 are investigating whether colchicine and
methotrexate, respectively, reduce the incidence of car-
diovascular events in patients with coronary artery dis-
ease. Finally, the benefit of canakinumab was
demonstrated in patients with high CRP levels but its
effects in patients with low CRP remain to be estab-
lished, while that of LDL-lowering drugs does not
seem to be restricted to this subgroup. Although
lipid-lowering therapy is not free of adverse effects,71
it has been consistently demonstrated to be a safe ther-
apy, and even achieving very low LDL levels shows an
acceptable risk/benefit balance.65 On the other hand IL-
1b blockade may confer a higher risk of developing
fatal infections and sepsis7 and requires further study
due to the scarce amount of information available
regarding this point.
Finally, the inclusion criteria of CRP> 2mg/L in
CANTOS and the subgroup analysis performed
according to CRP in this trial underline the need to
improve risk stratification in patients with atheroscler-
osis. In addition to assessing LDL levels, it is true that
CRP levels and even IL-1b genotype72 have been sug-
gested to guide personalized medicine in an effort to
further reduce the residual burden in high cardiovascu-
lar-risk patients. However, the role of these and other
inflammatory biomarkers or even imaging strategies to
better select high-responders to therapeutic moieties
targeting either residual lipid or inflammatory path-
ways remains to be established73 and their use is not
recommended at present.74,75
Concluding remarks and open questions
1. Interplay between lipids and inflammation. The reduc-
tion in cardiovascular events observed with IL-1b
blockade confirms the link between lipids and
inflammation. The mechanism involves cholesterol
crystals (and possibly other lipid species) that acti-
vate major inflammatory pathways (TLRs or the
NLRP3) inducing maturation and release of IL-1b,
which is blocked by canakinumab.
2. Other pro-inflammatory targets appear worth testing.
Although IL-1b blockade is today the only anti-
inflammatory approach shown to significantly
reduce cardiovascular risk in a randomized clinical
trial for patients with cardiovascular disease, the
wealth of evidence linking inflammation with
atherosclerosis indicates that other potential targets
exist to be evaluated in future trials. In addition,
tools other than antibodies, such as interference
RNAs, may be tested to inhibit IL-1b.
3. Anti-inflammatory vs. LDL-lowering therapy in car-
diovascular prevention. Canakinumab is not a com-
petitor of LDL-lowering therapies given, among
other reasons, that the large evidence supporting
these therapies cannot be compared with the results
of only one clinical trial.
4. Potential role of anti-inflammatory therapy in cardio-
vascular prevention. Although the results of the
CANTOS trial can be considered a milestone in car-
diovascular medicine, canakinumab prescription for
patients with cardiovascular risk to improve their
prognosis needs to overcome certain hurdles. In
this regard, the results of the ongoing CIRT and
COLCOT trials will clarify whether the cardiovascu-
lar benefit of IL-1b blockade extends to other anti-
inflammatory drugs that work through different
mechanisms, as this could represent a change on
the horizon of the treatment of atherosclerosis.
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